2023
Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress
Rahman S, Ryan S, Kim J, Kenney P, Ghali F. Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress. European Urology Focus 2023, 9: 861-862. PMID: 38042649, DOI: 10.1016/j.euf.2023.11.011.Peer-Reviewed Original ResearchMetastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Ghali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaVariant histologySacituzumab govitecanTrop-2Nectin-4Antibody-drug conjugatesMetastatic lesionsADC targetCytoplasmic stainingProminent cytoplasmic stainingMembrane stainingTrop-2 expressionCytoplasmic protein expressionMetastatic sitesAutopsy studyUrothelial carcinomaMetastatic tumorsSquamous differentiationClinical relevanceCancer expressionHistologyNeuroendocrineProtein expressionMRNA levelsProtein levelsThe Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities
Ghali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.Peer-Reviewed Original Research
2022
External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study
Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.Peer-Reviewed Original ResearchConceptsNew-onset CKDCKD stageChronic kidney disease developmentExternal validationCKD stage ICT1 renal massesKidney disease developmentPreoperative eGFRPatient ageConsecutive patientsMulticenter studyTumor sizePartial nephrectomyRenal massesProgression rateGood calibration propertiesStage IProgression probabilityPatientsNomogramIndividual riskCKDDisease developmentEGFRMedian valueImpact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomyDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive marginsDisparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic
Javier-DesLoges J, Meagher M, Soliman S, Yuan J, Hakimi K, Ghali F, Nalawade V, Patel DN, Monga M, Murphy JD, Derweesh I. Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic. Urology 2022, 163: 76-80. PMID: 34979219, PMCID: PMC8719918, DOI: 10.1016/j.urology.2021.11.037.Peer-Reviewed Original ResearchConceptsTelemedicine utilizationMultivariable logistic regression analysisLogistic regression multivariable analysisRegression multivariable analysisSingle academic institutionLogistic regression analysisUse of telemedicineCOVID-19 pandemicNon-Hispanic whitesUrology patientsPatient characteristicsPrimary outcomeMedicaid insuranceMultivariable analysisRetrospective studyTelemedicine appointmentsUrologic conditionsProvider ageProvider trainingClinic locationProvider sexPatientsBackward model selectionZip codesVisits
2021
Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients
Javier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.Peer-Reviewed Original ResearchConceptsNon-Hispanic white patientsCancer-specific survivalRenal cell carcinomaMedically Underserved AreasCause mortalityWhite patientsHealth care system accessSpecific survivalNon-Hispanic whitesLocalized Renal Cell CarcinomaTertiary referral centerCause mortality riskKaplan-Meier analysisLog-rank testCancer surgical outcomesOverall survivalReferral centerSecondary outcomesPrimary outcomeHispanic patientsMeier analysisCox regressionSurgical outcomesCell carcinomaRisk factorsRe: Association of Black Race with Prostate Cancer–specific and Other-cause Mortality
Ghali F, Kane C. Re: Association of Black Race with Prostate Cancer–specific and Other-cause Mortality. European Urology 2021, 80: 758-759. PMID: 34535345, DOI: 10.1016/j.eururo.2021.09.004.Peer-Reviewed Original ResearchWarm ischemia time length during on-clamp partial nephrectomy: dose it really matter?
Abdel Raheem A, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, DE Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Tadifa J, Santok G, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Aguilera Bazan A, Ballesteros Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Alwahabi A, Alqahtani A, Rumaih A, Ghaith A, Ghoneem A, Hagras A, Eissa A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter? Minerva Urologica E Nefrologica 2021, 74: 194-202. PMID: 34308610, DOI: 10.23736/s2724-6051.21.04466-9.Peer-Reviewed Original ResearchConceptsClamp partial nephrectomyWarm ischemia timePartial nephrectomyEGFR preservationCKD stageEGFR valuesProgression rateGroup IILong-term renal functionGroup ILong-term renal function outcomeUnivariable Cox regression analysisMedian eGFR valueRenal function outcomesInternational cohort studyRenal functional recoveryCox regression analysisML/Regression analysisDisease upgradingEGFR declineEGFR changeCohort studyRenal functionFinal cohortEvaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act
Javier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.Peer-Reviewed Original ResearchConceptsLow-income patientsRenal cell carcinomaAffordable Care ActACA implementationNonexpansion statesLocalized diseaseAbsolute percentage changeCell carcinomaCancer stageExpansion statesNational Cancer DatabaseProportion of patientsRetrospective cohort analysisInsurance coveragePatient ProtectionCare ActMedicaid expansion statesInsurance coverage statusLow-income adultsEarly RCC detectionExpansion of insuranceSecondary outcomesInsurance statusAdjusted differenceCancer DatabaseA Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)
Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo R, Sundaram C, Rha K, Gonzalgo M, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu A, Mottrie A, Abdollah F, Eun D, Derweesh I, Veccia A, Autorino R, Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). European Urology Focus 2021, 8: 173-181. PMID: 33549537, DOI: 10.1016/j.euf.2021.01.014.Peer-Reviewed Original Research
2020
Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database
Patel DN, Ghali F, Meagher MF, Javier-Desloges J, Patel SH, Soliman S, Hakimi K, Yuan J, Murphy J, Derweesh IH. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2020, 39: 79.e1-79.e8. PMID: 33160847, DOI: 10.1016/j.urolonc.2020.10.015.Peer-Reviewed Original ResearchConceptsUse of RMBRenal mass biopsyRenal cell carcinomaNational Cancer DatabaseCell carcinomaMultivariable analysisCancer DatabaseMass biopsyCharlson Comorbidity IndexCurrent guideline recommendationsYear of diagnosisPopulation-based studySmall renal massesComorbidity indexSurgical treatmentGuideline recommendationsTumor sizeRenal massesPersistent underutilizationPatientsCarcinomaStudy periodTumorsBiopsyHigh ratePathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy
Ghali F, Daly W, Hansen M, Hayn M, Sammon J, Beaule L, Sarkar R, Murphy J, Kader A, Derweesh I, Rose B, Ryan S. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology Seminars And Original Investigations 2020, 39: 130.e1-130.e7. PMID: 33121914, DOI: 10.1016/j.urolonc.2020.08.035.Peer-Reviewed Original ResearchConceptsNodal statusRadical prostatectomyOverall survivalDiscordant stagingDiscordant statusSimilar OSLymph nodesClinical positive lymph nodesNational Cancer Data BaseClinical nodal stagingDefinitive locoregional therapyPathologic nodal statusUnderwent radical prostatectomyPositive lymph nodesPositive nodal statusLow Gleason scoreNegative node statusDifficult clinical scenariosKaplan-Meier estimationCharlson indexClinical nodalCM1 diseaseCT1-3Noncurative therapyPathologic nodalImpact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database
Ryan S, Patel D, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta B, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. Minerva Urologica E Nefrologica 2020, 73: 233-244. PMID: 32748614, DOI: 10.23736/s2724-6051.20.03728-5.Peer-Reviewed Original ResearchConceptsPositive surgical marginsKaplan-Meier analysisRenal cell carcinomaNational Cancer DatabaseOverall survivalPartial nephrectomyMultivariable analysisSurgical marginsPathological stageCancer DatabaseCox regression multivariable analysisN0M0 renal cell carcinomaUS National Cancer DatabaseImpact of PSMRegression multivariable analysisPT3a diseaseCause mortalityMargin statusNegative marginsResection strategyCell carcinomaAggressive surveillanceRetrospective analysisKidney cancerPatientsComparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma
Meagher M, Lane B, Capitanio U, Mehrazin R, Bradshaw A, Noyes S, Larcher A, Eldefrawy A, Ghali F, Patel D, Bruinius J, Dutt R, Keiner C, Miller N, Wan F, Montorsi F, Derweesh I. Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World Journal Of Urology 2020, 39: 1195-1201. PMID: 32556559, DOI: 10.1007/s00345-020-03299-5.Peer-Reviewed Original ResearchConceptsDe novo chronic kidney diseaseChronic kidney diseaseKaplan-Meier analysisPartial nephrectomyActive surveillanceMultivariable analysisBaseline eGFRTumor sizeFunctional outcomeFunctional declineCKD-free survivalGreater functional declineHigher RENAL scoreLower baseline eGFRRenal functional preservationRegression multivariable analysisClinical tumor sizeRenal functional outcomesTumor diameterKidney diseaseRENAL scoreFunctional preservationMedian changeRetrospective analysisSelect circumstancesRates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.Peer-Reviewed Original ResearchConceptsCytoreductive nephrectomyPostoperative complicationsMultivariable analysisMRCC patientsIntraoperative complicationsBlood lossSignificant predictorsComplex surgeryMetastatic renal cell carcinoma patientsHigh-grade postoperative complicationsHigher intraoperative blood lossMetastatic renal cell carcinomaRenal cell carcinoma patientsCase loadHigh-grade morbidityMultiple postoperative complicationsIntraoperative blood lossMetastatic renal cancerCell carcinoma patientsPrimary kidney tumorsRenal cell carcinomaLogistic regression analysisTherapy eraPerioperative complicationsPostoperative morbidityOncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.Peer-Reviewed Original ResearchConceptsKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaRecurrence-free survivalRadical nephrectomyPartial nephrectomyOverall survivalMultivariable analysisCell carcinomaFunctional outcomeDe novo eGFRGlomular filtration rateClinical T stageMulticenter retrospective analysisRisk of recurrenceMulti-institutional analysisPT3a upstagingOncologic outcomesSecondary outcomesPrimary outcomeIndependent predictorsSurvival outcomesT stagePositive marginsPredictive factors
2019
Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria
Hamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRisk of recurrenceRenal cell carcinomaKaplan-Meier analysisHigher clinical stageClinical stageOverall survivalMultivariable analysisPT3a upstagingRisk factorsTumor-NodeT3a renal cell carcinomaRenal cell carcinoma patientsRisk of upstagingCell carcinoma patientsMulticenter retrospective analysisPerinephric fat invasionInitial clinical stageRenal vein invasionType of surgeryPT3a diseaseCarcinoma patientsPrimary outcomeFat invasionRenal veinRobotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis
Ghali F, Elbakry A, Hamilton Z, Yim K, Nasseri R, Patel S, Eldefrawy A, Ryan S, Bradshaw A, Meagher M, Bree K, Reddy M, Lee H, Derweesh I. Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis. World Journal Of Urology 2019, 38: 1113-1122. PMID: 31701211, DOI: 10.1007/s00345-019-02994-2.Peer-Reviewed Original ResearchConceptsPartial nephrectomyOpen PNRenal massesMultivariable analysisRENAL scoreResultsMean tumor sizeLower blood lossBurden of morbidityFirst-line optionT2 renal massesOpen partial nephrectomyRobotic partial nephrectomyMedian RENAL scoreAchievement of trifectaEGFR recoveryHospital staySelect patientsBlood lossConsecutive patientsMajor complicationsMethodsRetrospective analysisPositive marginsTumor sizeFunctional outcomeTrifecta achievement